Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: Aug 13, 2025
Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025
Read more at globenewswire.com9.66
-0.4 (-3.98%)
Find more stocks in the Stock Screener
KLRS Latest News and Analysis
